• The company was founded in 2012.

• Submitted IND clinical trial application for Azvudine for the treatment of HIV infection.

• Approval granted by the NMPA to conduct Phase I clinical trials of Azvudine for the treatment of HIV infection in China.

• Conducted Phase I clinical trials of Azvudine for the treatment of HIV infection in China.

• Completed Phase I clinical trials of Azvudine for the treatment of HIV infection in China.

• Approval granted by the NMPA to conduct Phase II clinical trials of Azvudine for the treatment of HIV infection in China.

• Conducted Phase II clinical trials of Azvudine for the treatment of HIV infection in China.

• Completed Phase II clinical trials of Azvudine for the treatment of HIV infection in China.

• Established Shenzhen Genuine Biotech Co., Ltd. and Shenzhen R&D Center.

• Approval granted by the NMPA to conduct Phase I/II clinical trials of dosimertinib for the treatment of advanced EGFR mutation-positive non-small cell lung cancer in China.

• Approval granted by the NMPA to conduct Phase III clinical trials of Azvudine for the treatment of COVID-19.

• The application for Phase III clinical trials of Azvudine for the treatment of COVID-19 in Russia and Brazil was approved, and clinical trials started in Jun. 2021.

• Completed the Series A Investment and raised approximately RMB 149.5 million.

• Obtained a conditional NDA approval for Azvudine from the NMPA for treating HIV infection in China.

• Completed Phase III clinical trials of Azvudine for treating COVID-19 in China.

• Completed the Series B Investment and raised approximately RMB 563.3 million.

• Obtained a conditional approval for Azvudine from the NMPA for treating common COVID-19 in adults in China.

• Entered into a strategic cooperation agreement with Fosun Pharmaceutical Industrial.

• Azvudine tablets was the only domestic oral drug included in the Chinese Diagnosis and Treatment Guideline for COVID-19 (9th Edition).

• The IND application of CL-197, the next-generation oral long-acting HIV drug candidate, was approved by the NMPA.

• Azvudine was approved for marketing by the Ministry of Health of the Russian Federation (registration certificate no.: ЛП-008750) and officially became a drug for the treatment of COVID-19 in Russia.

• Genuine Biotech jointly with Fosun Pharma donated 100 million yuan's worth of Azvudine to rural areas in Midwestern China, covering 180 counties.

• Azvudine was officially included in the national reimbursement drug list.

• Azvudine was included in the Chinese Diagnosis and Treatment Guideline for COVID-19 (Tentative 10th Edition).